IPM clocks Rs 7294 crores revenue in January 2015

31 corporates have shown growth more than 10 per cent amongst the top 50

In January 2015, the Indian Pharma Market (IPM) has clocked Rs 7294 crores in January 2015. It has grown at 12.7 per cent in the said month. Amongst the top 10, Ranbaxy grew by 28 per cent followed by Pfizer at 25.8 per cent and Abbott at 15.1 per cent. 24 corporate have crossed the growth of IPM for the month of January 2015 amongst top 50. Amongst the top 50 corporate, Akumentis has the highest growth of 68.6 per cent followed by Ranbaxy at 28 per cent and JBCPL at 27.3 per cent. 31 corporates have shown growths more than 10 per cent amongst the top 50.

Amongst the 11-20 ranked corporate, Sanofi has the highest growth of 25.1 per cent followed by Macleods and Torrent at 25 per cent and Glenmark at 21.3 per cent. Amongst the 51-60 ranked corporates, Panacea grows at 32.5 per cent followed by Systopic at 20.1 per cent and Centaur at 15.1 per cent. Amongst the 61-70 ranked corporates, Boehringer grew by 70.4 per cent followed by TTK at 25.4 per cent and Tablets India at 18.9 per cent.

Mankind and Alkem have entered the Rs 3000 crore club, Wockhardt has entered the Rs 1000-crore club, Himalaya entered the Rs 500-crore club, Fresenius Kabi, Serdia and Charak Pharma entered the Rs 150 crore-club as on MAT Jan 2015.

Indian companies have grown at 11 per cent versus 17.7 per cent for MNCs in January 2015. Amongst the top 50 in MNCs, Ranbaxy grew by 28 per cent followed by Pfizer at 25.8 per cent and Sanofi & Merck at 25.1 per cent. Under the non-NLEM category Indian companies grew at 12.7 per cent whereas MNCs grew at 17.8 per cent.

The DPCO containing molecules market grew at 6.9 per cent whereas the non-DPCO market grew by 14 per cent resulting in an overall growth of 12.7 per cent for January 2015. The NLEM and Non – NLEM category showed unit growth at 1.8 per cent and 3.7 per cent respectively. The DPCO 2013 portfolio for Pfizer grew at 18.6 per cent, Ranbaxy 53.7 per cent and Abbott 21.2 per cent.

From therapy perspective. eight therapies have outgrown the IPM growth and 13 therapies have double digit growths. The respiratory market grew at 11.2 per cent, gastrointestinal market grew at 12.6 per cent, pain and analgesics market grew at 11.4 per cent whereas the anti-infectives grew at 7.6 per cent. The anti-diabetic market grew at 25.4 per cent and cardiac at 13.2 per cent in chronic business. The derma market grew by 18 per cent and the urology market at 51.5 per cent.

From regional perspective, 11 regions have outgrown the IPM growth. The Telangana market grew the highest at 23.6 per cent followed by Tamil Nadu and UP East market at 19.2 per cent and Rajasthan market at 18.7 per cent

• No regions had negative growth in January 2015
• Molecules
• Amoxycillin + Clavulanic Acid Market grew at 9.4 per cent whereas Glimepiride + Metformin grows at 12.9 per cent at No 2.
• The markets of Paracetamol grew at 10.3 per cent, Atorvastatin 14.9 per cent, Probiotic Microbes at 16.2 per cent, Cefixime 4.2 per cent, Pantoprazole 10.1 per cent, Montelukast + Levocetrizine at 18.0 per cent, Glimepiride + Metformin + Pioglitazone at 26.6 per cent, Vitamin-D at 29.9 per cent, Hydroquinone + Mometasone + Tretinoin at 23.7 per cent, Voglibose + Metformin + Glimepiride at 55.3 per cent, Rosuvastatin at 29.1 per cent, Protein Supplements at 15.7 per cent

Brands

• Mixtard continues to lead the pack with 38 crores for the Month of Jan -15
• Glycomet-GP grew at 23.2 per cent, Monocef at 32.8 per cent, Volini at 21.0 per cent and Lantus at 30.6 per cent amongst the top 10 brands

Few brands who have gained ranks include Januvia (+66), Shelcal (+63), Magnex (+60), Janumet (+59), Panderm Plus and Istamet (+44), Jalra M (+41), Rosuvas (+40), Clexane (+35), Storvas (+32), Thyronorm (+18), Allegra (+17), Taxim (+14), Dolo and Pantocid DSR(+12), Pan D (+11), Novomix (+7) amongst top 100 brands over January 13

New launches in IPM

• Total 337 SKUs and 174 brands launched in January 2015
• Novo Nordisk also launches full-fledged its diabetic drug Ryzodeg in India in Jan 2015
• Top new brands for January are Ketoadd, Abstet, Ketoplast

About PharmaTrac

PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.

Terminologies used
MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage.

For more information, visit http://www.aiocd.net